End-stage liver disease has become in recent years a leading cause of mortality in human immunodeficiency virus (HIV)-infected patients on antiretroviral therapy [1, 2] . The management of chronic C hepatitis in patients coinfected with HIV and hepatitis C virus (HCV) poses great clinical challenges, given a faster liver disease progression, reduced treatment response to pegylated interferon ( peg-IFN) and ribavirin (RBV) treatment [3, 4] , changes in drug concentrations [5] , and a potentially increased risk of infectious complications during treatment with peg-IFN + RBV [6] .
Indeed, infections are common during treatment of chronic hepatitis C with peg-IFN + RBV [7] [8] [9] [10] [11] [12] ; despite lacking data from clinical trials to support an association, infections have been traditionally related to peg-IFN-induced neutropenia. Consequently, neutropenia has been the most common cause of dose reductions [13] , which significantly impair the rate of sustained virologic response [14] . Filgrastim, a human granulocyte colony-stimulating factor (G-CSF), is commonly used off-label to ameliorate neutropenia, prevent serious infections, and avoid peg-IFN dose reductions. However, little evidence supports the use of G-CSF in such scenarios [15] . Along with the fact that filgrastim can potentially cause severe adverse effects and is costly, the association between peg-IFN-induced neutropenia and increased rates of infection is debated [10] . Indeed, life-threatening infections occur rarely in such scenarios [8, 9, 15] , suggesting a lower risk for neutropenic infections in patients with chronic hepatitis C compared with immunosuppressed patients undergoing cancer chemotherapy [16, 17] . Furthermore, because large clinical trials reduced the peg-IFN dose to 50% when neutrophil counts dropped below 750 cells/μL and permanently when the threshold of severe neutropenia was reached (<500 cells/μL) [8, 9, 11, 12, [18] [19] [20] , this question has been addressed only in observational studies.
Studies describing infectious complications during treatment with peg-IFN + RBV in HIV/HCV-coinfected individuals found an important rate of mild to moderate infections unrelated to neutropenia [7, 11, 21] , suggesting that neutropenia does not correlate with the rates of fungal, viral, or bacterial infections. However, given the low incidence of life-threatening serious infectious complications and the sample sizes of previous studies, the question of whether severe neutropenia during peg-IFN treatment in HIV/HCV-coinfected subjects is associated with increased risk of serious infections remains to be answered. Again, despite little evidence in this clinical setting, in the advent of severe neutropenia during peg-IFN-based therapies, HIV infection is currently considered an indication of G-CSF use [22] . The rationale of this recommendation is to avoid the detrimental effect of peg-IFN dose reductions, which further decrease the suboptimal treatment response in HIV/ HCV-coinfected individuals [23] .
To provide additional insight into the relationship between severe neutropenia and the risk of serious infectious complications, we specifically evaluated the influence of neutropenia on the rate of serious infections in a large prospective cohort of HIV/HCV-coinfected patients who received treatment with peg-IFN + RBV.
METHODS

Study Design, Participants, Setting, and Eligibility
We conducted an observational prospective cohort study of 418 HIV/HCV-coinfected subjects initiating treatment with peg-IFN + RBV in a university-based HIV clinic in Madrid from 2000 to 2012. The eligibility criteria for anti-HCV therapy included absence of prior hepatic decompensation, stable antiretroviral therapy (ART) or no need for ART, CD4 cell count >200 cells/μL, absence of active opportunistic infections, and no active drug abuse. During treatment, monthly visits were performed and all adverse effects were systematically recorded, including follow-up after 6 months of therapy. Data were collected according to a protocol designed to evaluate the association between baseline characteristics, peg-IFN-induced neutropenia, and the risk of infections. The study conformed to the principles of the Declaration of Helsinki and Good Clinical Practice Guidelines and was approved by our local ethics committee. All patients gave their written informed consent to participate in the study.
Clinical and Laboratory Measurements
Medical records were carefully reviewed and all subjects underwent a physical examination. We collected data on age, sex, weight, HIV transmission category, previous AIDS-defining conditions, CD4 count during treatment, nadir CD4, baseline viral load, and use of ART. Information related to HCV infection included genotype, HCV RNA levels, alcohol intake, type of interferon-based therapy (peg-IFN alfa-2a or alfa-2b), peg-IFN dose reductions and duration of therapy, and concomitant use of other medications, including G-CSF. Other laboratory measurements included alanine aminotransferase, aspartate aminotransferase, neutrophil and platelet counts, and hemoglobin levels at baseline and during the course of therapy. Diagnosis of cirrhosis could be diagnosed by liver biopsy following the criteria established by the METAVIR Cooperative Study Group [24] or by liver stiffness evaluation using transient elastometry [25] .
Subjects were treated either with peg-IFN alfa-2a, 180 μg subcutaneously or peg-IFN alfa-2b, 1.5 μg/kg subcutaneously per week, plus weight-adjusted oral RBV, according to the corresponding updates of the HCV-HIV International Panel [26] .
Infections were routinely evaluated during treatment and documented by the managing clinician. Infectious were considered "serious" when patients required hospitalization, treatment discontinuation, or the patient died. The lowest neutrophil count during peg-IFN + RBV treatment was used to define neutropenia. Although definitions of neutropenia are variable from institution to institution, a neutrophil count <1500/μL is the generally accepted definition of neutropenia for adults, as well as the threshold for neutrophil toxicity and risk of infections following chemotherapy, and severe neutropenia is defined as an absolute neutrophil count of <500 cells/μL [16] .
Statistical Analysis
Qualitative variables were summarized as a frequency distribution and normally distributed quantitative variables as mean ± standard deviation. Continuous nonnormally distributed variables were summarized as median and interquartile range (IQR). Means for variables with a normal distribution were compared using the t test. Nonparametric variables were studied using the Mann-Whitney test. We analyzed 2 outcome variables, "all infections" (infections of any severity) and "serious infections." Patients who developed infections were compared with those who did not using the χ² test and a trend test for the comparison of the frequency of all infections and serious infections according to the category of neutropenia. A multivariate logistic regression model was built to evaluate potential predictors of all infections. The model was adjusted by those variables that in the univariate analyses showed a level of statistical significance of <.05 and/or were considered clinically relevant. The magnitude of association was evaluated using the odds ratio (OR) and its 95% confidence interval (CI). Another multivariate logistic regression analysis was designed to evaluate the association between neutropenia ( principal independent variable, as a dummy variable: no neutropenia [reference category], nonsevere neutropenia, and severe neutropenia) and the risk of serious infections (dependent variable). Given the number of events (20 serious infections), the mathematical modeling involved the calculation of the crude OR, with consecutive adjustment by the potential confounding effects of the covariates (secondary independent variables).
The null hypothesis was rejected by a type I error <.05. Statistical analyses were performed using SPSS software, version 15.0 (IBM, Chicago, Illinois).
RESULTS
General Characteristics of the Study Population
The 418 subjects included in the study involved 3928 personweeks of therapy with peg-IFN. Main characteristics of this cohort are summarized in Table 1 . The study population was representative of a middle-aged (mean, 41 ± 5 years) HIV/ HCV-coinfected population with a history of previous injection drug use (89%), and almost half of patients (45%) had a diagnosis of cirrhosis. Most patients were on ART (85%), with a good immunological status (median CD4 count, 487 cells/μL). Neutropenia was common, with a 65% of patients developing moderate neutropenia (<1500 cells/μL) and 8% severe neutropenia (<500 cells/μL). Forty-eight (11%) patients received G-CSF during treatment, with a median neutrophil count of 500 cells/μL (IQR, 400-700). These subjects receiving G-CSF showed a lower CD4 nadir ( ; P = .075), with no significant differences in other variables such as age, previous AIDS diagnosis, or cirrhosis. We did not detect statistically significant differences in the use of G-CSF and the frequency of peg-IFN + RBV dose reductions, treatment interruptions, or the rate of sustained virological response between the 35 subjects with severe neutropenia and those who did not develop severe neutropenia (data not shown).
Description of All Infections and Associated Factors
Infections occurred in 123 (29%) subjects, accounting for 149 episodes (3.8 infections per 100 person-weeks of therapy). Types of infections are listed in Table 2 . Nearly half of Figure 1 illustrates the frequency of infections according to the category of neutropenia. Subjects with severe neutropenia and nonsevere neutropenia more frequently developed infections compared to those without neutropenia; however, the differences did not reach statistical significance (34.3%, 32.5%, and 22.5%, respectively, trend test P = .067).
A multivariate logistic regression model was built to analyze potential predictors of all infections during peg-IFN + RBV treatment. The model included the following variables: age, sex, lowest CD4 count during treatment, AIDS, use of ART, cirrhosis, neutrophil count, type of peg-IFN, and G-CSF use. After the multivariate analysis, none of these variables remained independently associated with the risk of infection (Table 3) .
Description of Serious Infections
There were 20 episodes of serious infections (4.8% of all patients), accounting for 0.5 episodes per 100 person-weeks of therapy, including 7 cases of pneumonia, 3 of primary bacteremia, 2 of spontaneous bacterial peritonitis, 2 of acute gastroenteritis, 2 of acute pyelonephritis, 1 of Clostridium difficile diarrhea, 1 of mandibular abscess, 1 of acute prostatitis, and 1 of Fournier gangrene. There were no associated deaths. Table 4 summarizes the characteristics of patients who developed serious infections.
Influence of Neutropenia on the Risk of Serious Infections
To analyze the association between severe neutropenia and the rate of serious infections, we compared the frequency of serious infections among patients with severe neutropenia, those with nonsevere neutropenia, and those without neutropenia. The frequency of serious infections was higher in subjects with severe neutropenia compared to those with nonsevere neutropenia and without neutropenia (8.6%, 4.8%, and 3.6%, Figure 1 . Frequency of infections according to the presence of severe neutropenia, nonsevere neutropenia, and no neutropenia. Although subjects with severe neutropenia and nonsevere neutropenia more frequently developed infections compared to those without neutropenia, the difference did not reach statistical significance (34.3%, 32.5%, and 22.5%, respectively, trend test P = .067). Similarly, the frequency of serious infections was higher in subjects with severe neutropenia compared to those with nonsevere neutropenia and without neutropenia (8.6%, 4.8%, and 3.6%, respectively), and this difference did not reach the level of statistical significance (trend test P = .281). respectively). However, these differences did not reach the level of statistical significance (trend test P = .281; Figure 1 ). Finally, we evaluated the influence of neutropenia (3 categories as a dummy variable: no neutropenia as the reference category, nonsevere neutropenia, and severe neutropenia) on the risk of serious infections (dependent variable) by a series of logistic regression analyses. In the crude analysis, neutropenia was not associated with the risk of serious infections (severe neutropenia: OR, 2.5; 95% CI, .5-11.8; nonsevere neutropenia: OR, 1.4; 95% CI, . 4-4.2) . This association remained unchanged after consecutive adjustment by age, sex, CD4 count, AIDS, ART, cirrhosis, peg-IFN dose reduction, and G-CSF use (Table 5) . Hence, we did not detect any significant association between neutropenia (severe and nonsevere) and the risk of serious infections.
DISCUSSION
In this cohort study of 418 HIV/HCV-coinfected patients, we described infectious complications during peg-IFN + RBV treatment and analyzed risk factors for infection. Moreover, we evaluated the specific influence of neutropenia on the risk of serious infections. To the best of our knowledge, this is the largest study investigating the association between neutropenia and infection in HIV/HCV-coinfected individuals, with an important proportion of patients developing severe neutropenia (8%).
In our study, infectious complications were common during peg-IFN + RBV treatment: almost one-third of patients developed an infection. However, most infections were minor and involved the upper respiratory tract (47%). Among all the potential risk factors for infection, including neutrophil count The association between neutropenia and the risk of serious infections was evaluated by a series of regression logistic analyses. After consecutive adjustment by age, sex, CD4 count, AIDS, antiretroviral therapy, cirrhosis, peg-IFN dose reduction, and G-CSF use, neutropenia was not independently associated to increased risk of serious infections.
Abbreviations: CI, confidence interval; G-CSF, granulocyte colony-stimulating factor; OR, odds ratio; peg-IFN, pegylated interferon; Ref, reference category. and G-CSF use, none was significantly associated with the risk of infections. However, both serious and nonserious infections were more common among subjects with severe neutropenia, without reaching statistical significance. More importantly, after a series of multivariate analyses specifically designed to evaluate the influence of neutropenia on the development of serious infections, we found no statistically significant association between neutropenia and the advent of serious infectious complications. Previous studies analyzing infections during treatment with peg-IFN in HCV-monoinfected patients described an infection rate between 18% and 48%, and unrelated to neutropenia [7, 10, 11, 15, 21] . Fewer studies have addressed this problem in HIV/HCV-coinfected individuals, reporting infection rates of 35%-38% [6, 27] and again, with any correlation to neutropenia, arguing against the use of G-CSF. Cooper et al published in 2006 the first study in HIV/HCV-coinfected patients. From 25 patients, 11 were treated with nonpegylated IFN and 14 with peg-IFN. No patient with neutrophil count <750 cells/μL developed infection. In addition, no serious infection was recorded and importantly, no patient received G-CSF [27] . Later on, a larger study by Payer et al compared the incidence, type, and severity of infections in 85 HIV/HCVcoinfected and 164 monoinfected subjects [6] . The rate of infection was significantly higher in HIV/HCV-coinfected than HCV-monoinfected subjects (38% vs 15%), and as we report in our study, most common infections were minor upper respiratory tract infections, reporting also 5 cases of serious infections unrelated to neutropenia. Importantly, conclusions of this study were drawn on the basis only of univariate analyses and the specific association between neutropenia, and serious infection was not explored. Thus, an important question yet to be addressed was whether serious infection complications in HIV/ HCV-coinfected patients are associated with neutropenia. As shown by previous studies and ours, most frequent infections during treatment with peg-IFN and RBV are trivial and the use of G-CSF would probably not be justified even if a relationship with neutropenia were demonstrated. Contrarily, a relationship between neutropenia and life-threatening infections would probably favor G-CSF use, even in the case of a low rate of events. In our study, no statistical differences were observed between subjects who developed serious infections and those who did not, in agreement with current knowledge on associated risk factors for all-severity infections during treatment for chronic hepatitis C. However, the frequency of serious infections was strikingly higher in patients with severe neutropenia (8.6%) compared to those without neutropenia (3.6%), with borderline statistical significance in the trend test for all infections (P = .067). Thus, we are concerned by the fact that the low number of serious infections (n = 20) has probably limited the power of statistical analyses to detect such an association. In our view, these data protract the debate on the influence of peg-IFN-induced severe neutropenia on the risk of serious infections and disagree with previous studies reporting no correlation between neutropenia and infections [6, 7, 27] .
Our study is subject to a series of limitations. Because most of infections involved the respiratory tract, it would have been interesting to adjust the multivariate analyses for other potential confounders of respiratory infection, such as chronic obstructive lung disease, smoking status, or pneumococcal vaccination, information that was unavailable in the majority of the study population. Also, observational studies can support, but never prove, a lack of association between a risk factor (severe neutropenia) and a clinical event (serious infection). As described, the low frequency of serious infections precluded us from extensive multivariate modeling and hence, we cannot draw categorical conclusions. A substantially larger study might be necessary to detect statistically significant differences. We believe that a clinical trial randomizing subjects to receive or not receive G-CSF in the advent of severe neutropenia would definitively answer this question and would be ethically justified. Nevertheless, our study is consistent with previous data failing to demonstrate a statistically significant association between peg-IFN-induced neutropenia and infections, even in complex patients such as those coinfected with HIV and HCV.
In conclusion, we herein analyzed associated risk factors for infectious complications during peg-IFN + RBV treatment in the largest cohort of HIV/HCV-coinfected subjects to date. Our results support previous data showing a lack of association with different risk factors, including neutropenia, and provide new insight by showing no relationship between severe neutropenia and the development of serious infections.
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